Furthermore, vasculitis, characterized by inflammation in the blood vessels, and specifically, giant cell arteritis/large vessel vasculitis, represents a distinct irAE whose onset and frequency differ based on the specific ICIs utilized, being more frequently reported with anti-PD1/PD-L1 inhibitors, with the highest incidence when the combination of anti-PD1/PD-L1 and CTLA4 inhibitors are used [131]. This evidence concerns the gene PDCD1 and Large vessel vasculitis.